Contents

Search

lipoprotein-associated phospholipase A2 (Lp-PLA2) in serum/plasma

Indications: - cardiovascular risk assessment - risk for coronary artery disease - may be screening test of choice to predict cardiovascular risk in black women [3] Clinical significance: - increased levels associated with increased risk of coronary artery disease

Related

phospholipase A2 group 7; platelet-activating factor acetylhydrolase; PAF acetylhydrolase; PAF 2-acylhydrolase; LDL-associated phospholipase A2; LDL-PLA2; lipoprotein-associated phospholipase A2; 2-acetyl-1-alkylglycerophosphocholine esterase; 1-alkyl-2-acetylglycerophosphocholine esterase (PAFAH, PLA2G7)

References

  1. Teitz Textbook of Clinical Chemistry and Molecular Diagnostics, 4th edition, Burtis CA, Ashwood ER, Burns DE (eds), Elsevier, St Louis, 2006
  2. Lipoprotein-Associated Phospholipase A2 Laboratory Test Directory ARUP: 81055 - Lp-PLA2, Lipoprotein-Associated Phospholipase A2, Activity (PLAC) Laboratory Test Directory ARUP: 3002266
  3. Young K, Fairchild DG, Di Francesco L FDA Clears Test to Help Predict Coronary Heart Disease Risk Physician's First Watch, Dec 17, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org - FDA News Release. December 15, 2014 FDA clears test that helps predict the risk of coronary heart disease. Study data show test predicts risk better in black women. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426799.htm